New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss ...

Please provide your email address to receive an email when new articles are posted on . Adults receiving nimacimab plus semaglutide had a 2.95 percentage point greater weight loss than semaglutide ...

Preclinical models indicate CRB-913 is 15-fold less brain-penetrant than monlunabant and has a 50 times lower brain-to-plasma ratio than rimonabant, both experimental drugs in the same class. Corbus’s ...

Patients dosed with an experimental Skye Bioscience obesity drug did not lose enough weight to meet the goals of a mid-stage study, dealing a setback to the biotech’s bid to revive a class of ...

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals in a deal that would give it control of a preclinical prospect and add $5 ...

Please provide your email address to receive an email when new articles are posted on . Patients on anti-obesity medication who had weight loss within 1 year after TJA may be at decreased risk for ...

“Weight-loss drug craze appears to curb obesity epidemic” (Reading Eagle, Dec. 29) is a one-sided article on the pros of obesity drugs without reporting on the negative effects that come with the use ...

Have you heard the story of a breakthrough weight loss medicine called rimonabant? As a once-a-day oral medicine, rimonabant was approved in Europe in 2006 based on randomized controlled trials ...